CHF Solutions Renamed Nuwellis As It Expands Beyond Heart Failure Therapy
The company is expanding beyond its traditional focus on heart failure to bring its Aquadex fluid-management technology to more critical care and pediatric patients. Nuwellis’ new ticker symbol on NASDAQ is NUWE.
You may also be interested in...
Nestor Jaramillo, who just finished his first quarter as CEO of CHF Solutions, told Medtech Insight how his company is making its Aquadex ultrafiltration technology part of the standard of care for heart failure patients and others with dangerous fluid overload.
The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.
Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.